Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vatalanib + bevacizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
vatalanib + bevacizumab is a combination therapy investigated for the treatment of refractory and advanced solid tumors. Vatalanib (PTK787/ZK222584) is an orally active small molecule tyrosine kinase inhibitor that targets all known vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), as well as platelet-derived growth factor receptor-beta (PDGFR-beta) and c-kit. Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptors. By combining a receptor-level inhibitor (vatalanib) with a ligand-level inhibitor (bevacizumab), the regimen aims to achieve a more comprehensive blockade of the VEGF signaling pathway to suppress tumor angiogenesis and growth. This specific combination was evaluated in a Phase I clinical trial (NCT00611793) sponsored by SCRI Development Innovations, LLC.
- Brand names
- Avastin
- Other names
- vatalanibbevacizumab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on vatalanib + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vatalanib + bevacizumab.